FDA 483 - Barclay, Luke, & Pillai Specialty Pharmacy, PLLC - December 09, 2022

This FDA Form 483 document details observations from an inspection of a pharmaceutical manufacturing facility. The inspection identified several deficiencies related to facility control, contamination prevention, quality control, and process validation.

Key observations include: * **Facility and Equipment Cleanliness:** Equipment and surfaces within the ISO 5 classified aseptic processing areas were visibly dirty and difficult to clean. * **Contamination Control:** Non-microbial contamination was observed in the production area. Additionally, unsealed, loose ceiling tiles were present in the cleanroom, posing a contamination risk. * **Hazardous Drug Handling:** The facility produced hazardous drugs without adequate containment measures to prevent cross-contamination. * **Quality Control - Identity and Strength Testing:** Drug products were released for distribution without appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient. Furthermore, the identity of each component of a drug product was not verified by conducting at least one test, including specific identity tests where applicable. * **Process Validation - Media Fills:** Media fills, intended to simulate aseptic processing, did not adequately simulate the most challenging or stressful conditions, indicating a potential weakness in process validation.

These observations suggest issues with the facility's quality system, manufacturing controls, and adherence to Good Manufacturing Practices (GMP). The lack of adequate testing for identity and strength, coupled with contamination issues and insufficient media fill simulations, indicates potential risks to drug product quality and patient safety.